Core Insights - The company reported third quarter earnings and is experiencing positive momentum in its business operations [1] - The company is on track to achieve 2% to 3% operational revenue growth, excluding Indore, with expectations for continued positive momentum into 2026 [2] - The company has successfully delivered 5 out of 6 positive pipeline readouts in the first half of the year, indicating strong execution against strategic priorities [2] - The company is committed to capital allocation priorities, planning to return over $1 billion to shareholders, which includes $500 million in share repurchases this year [3]

Summary of Viatris Conference Call Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Event**: UBS Healthcare Conference - **Date**: November 11, 2025 Key Updates and Financial Performance - Viatris reported a positive momentum in business with an expected operational revenue growth of **2-3%** for 2025, excluding Indor [4][80] - The company is on track to return over **$1 billion** to shareholders, including **$500 million** in share repurchases for the year [4][80] New Product Launches - Anticipated new product revenue is projected to be in the range of **$450 million to $550 million** annually, driven by existing products and upcoming launches [6][4] - Key products contributing to this revenue include: - **Iron sucrose** - **Glucagon** - **Paclitaxel** - Upcoming launches: **Liraglutide**, **Effexor GAD**, **Sotagliflozin** [6][4] Geographic Performance - **North America**: - Experienced competition in generic products, particularly **XULANE LO** [17][22] - Decline primarily attributed to the impact of Indor [19][22] - Strong double-digit growth noted in products like **Breyna** and **Uptravi** [22][22] - **Emerging Markets**: - Strong growth driven by established brand business, particularly in **Turkey**, **Mexico**, and **emerging Asia** [23][23] - Stabilization of lower-margin ARV products has supported growth in the generics business [23][23] - **Japan**: - Facing normal price regulations but focusing on adding innovative assets to stabilize and grow the business [26][26] - Recent acquisition of **Pitolisant** and **Spidea** expected to enhance the portfolio [26][26] - **China**: - Achieved **9% operational growth** driven by a diversified commercial model and strong brand demand [28][28] - Over **10,000 customers** across various channels, with expectations for low to mid-single-digit growth over time [31][31] Pipeline and Future Products - Excitement around **fast-acting meloxicam** as a non-opioid alternative for acute pain management, targeting a launch in the second half of **2026** [34][41] - Anticipated FDA filings for several products, including **Effexor GAD** and **Salatogrel**, with enrollment for Salatogrel on track to complete by the end of **2026** [51][52] Indor Remediation and Strategic Review - Progress on remediation efforts for Indor, with operational readiness for reinspection expected in **2026** [54][54] - An enterprise-wide strategic review initiated to ensure sustainable growth, with details expected in **Q1 2026** [60][60] Capital Allocation Strategy - Viatris maintains a balanced capital allocation strategy, focusing on business development and capital return, with a **50/25/25** framework [71][71] - The company is looking for opportunities to invest in durable, higher-margin innovative assets, particularly in the U.S. market [73][73] Conclusion - Viatris is optimistic about its position going into **2026**, with a focus on executing its strategic priorities, enhancing its product pipeline, and addressing challenges in various markets [80][80]

Financial Data and Key Metrics Changes - Theravance Biopharma achieved non-GAAP break-even in Q3 2025, reflecting strong execution and financial discipline [2][18] - The company ended the quarter with approximately $333 million in cash and no debt, indicating a robust financial position [4][18] - Collaboration revenue increased to $20 million, up 19% year-over-year, driven by YUPELRI's strong operating leverage [18] Business Line Data and Key Metrics Changes - YUPELRI net sales increased 15% year-over-year to $71.4 million, supported by strong demand growth and favorable net pricing [6][7] - Profit margins for YUPELRI reached record levels, with hospital volume increasing 29% year-over-year [7][9] - The hospital channel's share in the long-acting nebulized market reached approximately 21%, a new high since launch [7] Market Data and Key Metrics Changes - The strong growth trends for Trelegy are expected to lead to a $100 million milestone in 2026, with current sales performance exceeding required thresholds [4][17] - The company is on track to achieve near-term milestones totaling $75 million in Q4 2025, including $50 million for Trelegy and $25 million for YUPELRI [4][19] Company Strategy and Development Direction - Theravance is focused on advancing the pivotal phase III CYPRESS trial of ampreloxetine, with data readout expected in early 2026 [3][15] - The company aims to position ampreloxetine as the first precision therapy for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy [4][15] - A new disease education campaign for healthcare professionals was launched to raise awareness of neurogenic orthostatic hypotension associated with MSA [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of the CYPRESS study and the potential of ampreloxetine to be a significant value inflection point for the company [3][20] - The company is optimistic about the upcoming CYPRESS data readout, viewing it as a transformational catalyst with meaningful upside potential [20] - Management emphasized the importance of financial strength and operational efficiency in supporting future growth and capital returns to shareholders [22][23] Other Important Information - The company plans to host a KOL event for investors on December 8th to discuss the unmet medical needs of patients with MSA and the potential of ampreloxetine [4][16] - The operational execution of the CYPRESS study has been aligned with FDA guidelines, ensuring adequate powering for the trial [40] Q&A Session Summary Question: How is the company thinking about capital return to shareholders in light of Trelegy's performance? - Management highlighted the importance of financial strength and the need to evaluate capital return timing based on the execution of the CYPRESS study [22][23] Question: Are there any pipeline assets being considered for future development? - Management reiterated the focus on YUPELRI and ampreloxetine, stating that future options will be evaluated post-ampreloxetine success [25][26] Question: How does the recently published manuscript inform expectations for CYPRESS data? - Management noted that a one-point difference in the composite score is considered clinically meaningful and is crucial for the CYPRESS study [30][33] Question: Can the company share enrollment numbers for the CYPRESS study? - Management confirmed confidence in enrollment numbers and operational execution, stating that the study is adequately powered [40][41]

Financial Data and Key Metrics Changes - Theravance Biopharma achieved non-GAAP break-even in Q3 2025, reflecting strong execution and financial discipline [2][18] - The company ended the quarter with approximately $333 million in cash and no debt, indicating a solid financial position [4][18] - Collaboration revenue increased to $20 million, up 19% year-over-year, driven by UPELRI's strong performance [18] Business Line Data and Key Metrics Changes - UPELRI net sales increased 15% year-over-year to $71.4 million, supported by strong demand growth and favorable net pricing [6][18] - UPELRI's profit margins reached record levels, with hospital volume increasing 29% year-over-year [7][9] - The company is on track to achieve a $25 million milestone from Viatris based on UPELRI's year-to-date sales [3][6] Market Data and Key Metrics Changes - UPELRI's share in the long-acting nebulized hospital market reached approximately 21%, a new high since launch [7] - Strong growth trends for Trelegy are expected to lead to a $100 million milestone in 2026 [4][17] Company Strategy and Development Direction - Theravance is focused on advancing the pivotal phase III Cypress trial of ampraloxetine, with top-line results expected in early 2026 [3][15] - The company aims to position ampraloxetine as the first precision therapy for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy [4][15] - A new disease education campaign for healthcare professionals was launched to raise awareness of neurogenic orthostatic hypotension associated with MSA [5] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of the Cypress study and the potential of ampraloxetine to be a significant value inflection point for the company [3][20] - The company is optimistic about achieving near-term milestones totaling $75 million in Q4 2025 [4][19] - Management highlighted the importance of the upcoming Cypress data readout as a transformational catalyst for the company [20] Other Important Information - The company plans to host a KOL event for investors on December 8 to discuss the unmet medical need for patients with MSA and the potential of ampraloxetine [4][16] - The operational execution of the Cypress study has been aligned with FDA requirements, ensuring adequate powering for the trial [39] Q&A Session Summary Question: How does the company plan to balance returning capital to shareholders with the potential launch of ampraloxetine? - Management emphasized the importance of financial strength and the need to evaluate capital return timing based on the execution of the Cypress study [22][23] Question: Are there any pipeline assets being considered for future development? - Management stated that the current focus is on UPELRI and ampraloxetine, with potential evaluation of other options post-ampraloxetine success [25][27] Question: How does the recently published manuscript inform expectations for the Cypress data? - Management indicated that the publication is important for understanding the minimally clinically important difference needed for the Cypress study [30][33] Question: Can the company share enrollment numbers for the randomized withdrawal portion of the Cypress study? - Management confirmed confidence in enrollment numbers and operational execution, stating that the study is adequately powered [39][40]

Core Insights - Theravance Biopharma reported strong third-quarter results, achieving record net sales for YUPELRI and reaching non-GAAP breakeven, indicating financial and operational discipline [2][4][11] - The company is advancing ampreloxetine towards pivotal Phase 3 CYPRESS study topline results expected in Q1 2026, with a focus on addressing unmet needs in multiple system atrophy patients [2][3][15] Operational Highlights - YUPELRI net sales reached an all-time high of $71.4 million, a 15% increase year-over-year, driven by a 6% growth in customer demand and improved net pricing [4][5] - The open-label portion of the pivotal Phase 3 CYPRESS study for ampreloxetine is complete, with topline results anticipated in Q1 2026 [4][11] - The company plans to host a virtual Key Opinion Leader event on December 8, 2025, to discuss ampreloxetine's potential in treating neurogenic orthostatic hypotension [5][11] Financial Performance - Total revenue for Q3 2025 was $20.0 million, with Viatris collaboration revenue increasing by 19% compared to Q3 2024 [11][31] - R&D expenses for Q3 2025 were $8.1 million, down from $9.3 million in the same period in 2024, while SG&A expenses rose to $18.3 million from $16.9 million [11][31] - Net income for Q3 2025 was $3.6 million, a significant improvement from a net loss of $12.7 million in Q3 2024, aided by a $6.5 million income tax benefit [11][33] Strategic Initiatives - The company is preparing for an expedited NDA submission for ampreloxetine, contingent on supportive data from the ongoing study [5][15] - Theravance Biopharma continues to focus on disciplined capital allocation and returning excess cash to shareholders, with a Strategic Review Committee assessing strategic alternatives [18][20]

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Acquisitions and Strategic Focus - Viatris acquired Aculys Pharma for $35.0 million, gaining rights to develop pitolisant and Spydia® in Japan, expanding its innovative product portfolio [233] - The acquisition of Idorsia Products included an upfront payment of $350 million and potential milestone payments totaling up to $2.4 billion [243] - Viatris' strategic focus includes expanding its portfolio through acquisitions and innovative product development [220] - The company is continuously evaluating potential acquisitions and divestitures as part of its future growth strategy, which may impact future liquidity [328] Financial Performance - Total revenues for the three months ended September 30, 2025, were $3.76 billion, an increase of $8.7 million compared to $3.75 billion in the prior year period [249] - Net sales for the same period were $3.75 billion, reflecting an increase of $9.5 million, or essentially flat, compared to the prior year [253] - The company reported a net loss of $128.2 million for the three months ended September 30, 2025, compared to net earnings of $94.8 million in the prior year, representing a decrease of $223 million [249] - For the nine months ended September 30, 2025, total revenues were $10.60 billion, a decrease of $614.9 million compared to $11.21 billion in the prior year [249] - Net sales for the nine months ended September 30, 2025 were $10.56 billion, down $617.7 million or 6% compared to the previous year [278] - The company recorded a net loss of $3,174.8 million for the nine months ended September 30, 2025, compared to a net loss of $117.7 million for the same period in 2024 [312] Gross Profit and Margins - The gross profit for the three months ended September 30, 2025, was $1.37 billion, down $87.7 million from $1.46 billion in the prior year [249] - Gross profit for the nine months ended September 30, 2025 was $3.87 billion, with gross margins at 36%, down from $4.41 billion and 39% in the prior year [289] - Adjusted gross profit for the three months ended September 30, 2025 was $2.10 billion, with adjusted gross margins at 56%, compared to $2.19 billion and 58% in the prior year [264] - Adjusted gross profit for the same period was $5,952.4 million, resulting in an adjusted gross margin of 56%, down from 58% in 2024 [290] Expenses - R&D expenses increased by $52.0 million to $250.4 million for the three months ended September 30, 2025, primarily due to higher costs for development programs [265] - SG&A expenses decreased by $116.8 million to $886.6 million for the current quarter, mainly due to lower acquisition-related costs [266] - Selling, General and Administrative (SG&A) expenses decreased to $2.76 billion in 2025 from $3.06 billion in 2024, a reduction of $294.5 million attributed to divestitures and lower acquisition-related costs [293] - Interest expense decreased to $351.7 million in 2025 from $429.8 million in 2024, a reduction of $78.1 million due to debt repayments [297] Goodwill and Impairment - The company recorded a non-cash goodwill impairment charge of $2.9 billion due to increased business risks and uncertainties as of March 31, 2025 [236] - The company recorded a goodwill impairment charge of $2.94 billion for the nine months ended September 30, 2025, due to an interim goodwill impairment test [312] - The company performed goodwill impairment tests resulting in total impairment charges of $2,936.8 million across various reporting units as of March 31, 2025 [347] Market and Regulatory Environment - The FDA issued a warning letter and import alert for the Indore manufacturing facility, affecting 11 products distributed in the U.S. [237] - The company faces ongoing risks related to regulatory approvals and market acceptance of new products [227] - Viatris' Developed Markets segment includes operations primarily in North America and Europe, while the Emerging Markets segment covers over 125 countries [224] Cash Flow and Liquidity - Net cash provided by operating activities decreased by $320.1 million to $1.50 billion for the nine months ended September 30, 2025, compared to $1.82 billion in 2024 [315] - Net cash used in investing activities was $216.5 million for the nine months ended September 30, 2025, a decrease of $2.19 billion from net cash from investing activities of $1.97 billion in 2024 [318] - Cash and cash equivalents totaled $975.3 million at September 30, 2025, with significant investments in U.S. government money market funds and bank deposits [322] - The company has access to $3.5 billion under the 2024 Revolving Facility, which matures in September 2029, with no borrowings outstanding as of September 30, 2025 [323] Sales Performance by Region - Net sales in Developed Markets decreased by $43.1 million, or 2%, primarily due to the Indore Impact of approximately $100 million [258] - Net sales from Greater China increased by $53.4 million, or 10%, driven by strong growth across multiple channels [259] - Emerging Markets saw an increase in net sales of $37.2 million, or 7%, primarily due to higher volumes and pricing of existing products [261] - Net sales from Greater China increased by $114.9 million, or 7%, for the nine months ended September 30, 2025, driven by strong growth across multiple channels [283] Future Projections and Estimates - The North America reporting unit had a revenue compound annual growth rate forecast of approximately 3.1% over the next 10 years [347] - The Europe reporting unit had a revenue compound annual growth rate forecast of approximately 3.3% over the next 10 years [348] - The Emerging Markets reporting unit had a revenue compound annual growth rate forecast of approximately 3.5% over the next 10 years [349] - The revenue compound annual growth rate forecasted for the next 10 years is approximately 1.6% [352]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Insights - Viatris Inc. (VTRS) reported third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, exceeding the Zacks Consensus Estimate of 63 cents, but down from 75 cents in the same quarter last year [1][7] - Total revenues for the quarter were $3.76 billion, a 2% decline year over year on an operational basis, yet surpassing the Zacks Consensus Estimate of $3.6 billion [1][7] Revenue Breakdown - Total sales reached $3.7 billion, down 2% year over year, with a 1% decline on a divestiture-adjusted operational basis [3] - Sales from Developed Markets were $2.25 billion, down 5% on a divestiture-adjusted operational basis, but slightly above the Zacks Consensus Estimate of $2.20 billion [3] - Emerging Markets generated $570.4 million in sales, reflecting a 7% increase on a divestiture-adjusted operational basis, beating the Zacks Consensus Estimate of $550 million [4] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $306.3 million, down 9% on a divestiture-adjusted operational basis, yet exceeding the Zacks Consensus Estimate of $303 million [4] - Greater China sales amounted to $615.2 million, up 9% on a divestiture-adjusted operational basis, surpassing the Zacks Consensus Estimate of $579 million [4] Product Category Performance - Revenues from Brands increased by 3% to $2.4 billion, with a 1% rise on a divestiture-adjusted operational basis, driven by strong performance in Greater China and Emerging Markets [5] - Key branded products included Lipitor with sales of $396.1 million, Norvasc at $179.7 million, and EpiPen at $157.2 million, while Lyrica sales decreased to $126.5 million [8] Generics Performance - Generics revenue was $1.31 billion, down 5%, with a 6% decline on an operational change basis, primarily due to the impact from the Indore facility [9][10] - The decline in generics was offset by growth in complex products in North America and strong performance in key European markets [9] Financial Guidance and Shareholder Returns - Viatris raised its 2025 revenue guidance to a range of $13.9-$14.3 billion, up from the previous guidance of $13.5-$14 billion, and adjusted EPS guidance to $2.25-$2.35 from $2.16-$2.30 [12] - The company has returned over $920 million to shareholders year to date, including more than $500 million in share repurchases, and is on track to return over $1 billion in 2025 [11] Strategic Developments - Viatris acquired Aculys Pharma, gaining exclusive rights in Japan for pitolisant and plans to file two new drug applications in Japan [13] - The acquisition also includes rights for Spydia Nasal Spray, approved in Japan for treating status epilepticus [14]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $3.76 billion, down approximately 1% year-over-year. Excluding the impact from Indore, operational revenue growth was approximately 1% compared to the prior year [26][27] - Adjusted gross margin for the quarter was 56%, in line with expectations, but impacted by the Indore situation [28][29] - Free cash flow generated in the quarter was $658 million, with an adjusted figure of $728 million excluding transaction-related costs [29][30] Business Line Data and Key Metrics Changes - In developed markets, net sales decreased by 5%, primarily due to the Indore impact. However, the generics business grew by 5% year-over-year, driven by new product revenues in key markets like France and Italy [26][27] - The North America business saw a 12% decrease year-over-year, mainly due to the Indore impact and competition on certain generic products. Despite this, double-digit growth was observed in products like Breyna and Yupelri [27][28] - Emerging markets experienced a 7% increase in net sales, driven by established brands in key markets such as Turkey and Mexico [27][28] Market Data and Key Metrics Changes - In Japan, net sales decreased by approximately 9% due to government price regulations and changes in reimbursement policy affecting off-patent brands [27] - Greater China saw net sales exceed expectations with a growth of 9%, attributed to a diversified commercial model and increased demand for brands sensitive to patient choice [28] Company Strategy and Development Direction - The company is focusing on three key areas for sustained profitable growth: a global generics business evolving towards higher-margin complex products, an established brands business strengthened by adding brands, and an innovative brands business expanding through late-stage or in-market growth assets [6][7] - The strategic review aims to identify operating efficiencies across various functions, including sales, marketing, R&D, and supply chain, with an expectation of delivering meaningful net cost savings over a multi-year period [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the business, anticipating momentum to carry into 2026. They highlighted strong commercial execution and pipeline advancement as key drivers [5][11] - The company plans to provide a detailed outlook for 2026 in the first quarter of next year, considering factors such as timing of approvals and competitive dynamics [31][32] Other Important Information - The company has returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, and is on track to return over $1 billion for the year [10][30] - The acquisition of Aculys Pharma in Japan adds innovative CNS assets to the portfolio, strengthening the company's presence in a strategically important market [10][11] Q&A Session Questions and Answers Question: Update on the Indore resolution situation - Management reported significant progress in remediation efforts at the Indore facility and a productive meeting with the FDA regarding reinspection timing, which remains at the agency's discretion [36][37] Question: Performance of EpiPen and Lipitor - The strength of the Lipitor brand outside the U.S., particularly in China, has driven performance. EpiPen has seen stable market share, with strong growth in Europe following a relaunch in Canada [38][39] Question: Feedback from the FDA on fast-acting meloxicam - The company is optimistic about obtaining opioid-sparing language in the product label, with a pre-NDA meeting scheduled with the FDA to discuss this [44][45] Question: Capital allocation priorities for 2026 - The company aims for a balanced approach in capital allocation, focusing on both returning capital to shareholders and pursuing business development opportunities [46][47] Question: Insights on the enterprise-wide strategic review - Management indicated that significant cost savings are expected from the review, with a focus on various operational areas. Specific details will be provided in Q1 [51][52]